| Recruiting | Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-538 in Healthy Subjects Health Services Research | Phase 1 | 2026-03-13 |
| Not Yet Recruiting | Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Cutaneous Lupus Erythematosus (CLE) | Phase 2 | 2026-03-01 |
| Not Yet Recruiting | Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria Chronic Spontaneous Urticaria (CSU) | Phase 2 / Phase 3 | 2026-03-01 |
| Recruiting | Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis Plaque Psoriasis | Phase 2 | 2025-12-22 |
| Recruiting | Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis Prurigo Nodularis (PN) | Phase 2 | 2025-11-27 |
| Recruiting | A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lym Relapsed or Refractory Mantle Cell Lymphoma (MCL) | Phase 2 | 2025-08-21 |
| Not Yet Recruiting | Evaluation of ICP-B794 in Patients With Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2025-08-01 |
| Recruiting | ICP-332 in Subjects With Non-segmental Vitiligo Non Segmental Vitiligo | Phase 2 / Phase 3 | 2025-05-09 |
| Recruiting | Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis Plaque Psoriasis Patients | Phase 3 | 2025-03-20 |
| Not Yet Recruiting | Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Relapsed or Refractory Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | 2025-02-01 |
| Recruiting | ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS) | Phase 1 | 2024-12-18 |
| Recruiting | ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis Atopic Dermatitis | Phase 3 | 2024-11-14 |
| Recruiting | ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Ly Hematologic Malignancies | Phase 2 / Phase 3 | 2024-05-15 |
| Recruiting | Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplat DLBCL | Phase 3 | 2024-05-07 |
| Completed | Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Moderate to Severe Plaque Psoriasis | Phase 2 | 2024-01-04 |
| Recruiting | Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Pa Relapsed/Refractory Marginal Zone Lymphoma | Phase 3 | 2023-12-19 |
| Recruiting | Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopen Chronic Primary Immune Thrombocytopenia (ITP) | Phase 3 | 2023-10-26 |
| Recruiting | Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus Systemic Lupus Erythematosus, SLE | Phase 2 | 2023-04-29 |
| Unknown | Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multipl Relapsed and/or Refractory Multiple Myeloma | Phase 1 / Phase 2 | 2023-03-29 |
| Unknown | Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis Moderate to Severe Atopic Dermatitis | Phase 2 | 2023-03-18 |
| Unknown | Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject Hepatic Impairment | Phase 1 | 2023-03-17 |
| Recruiting | The Study of ICP-248 in Patients With Mature B-cell Malignancies Hematological Malignancies | Phase 1 | 2023-03-09 |
| Recruiting | Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hemato Advanced Solid Tumors and Hematologic Malignancies | Phase 1 | 2023-02-23 |
| Recruiting | Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors Advanced Solid Tumors Harboring NTRK Fusion, Primary Central Nervous System Tumors Harboring NTRK Fusion | Phase 1 / Phase 2 | 2022-12-27 |
| Unknown | Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects Healthy Subject | Phase 1 | 2022-11-19 |
| Recruiting | A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinom Intrahepatic Cholangiocarcinoma (ICC) | Phase 2 | 2022-11-15 |
| Unknown | A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphom Diffuse Large B Cell Lymphoma (DLBCL) | Phase 3 | 2022-11-02 |
| Unknown | A Clinical Study of ICP-488 in Healthy Subjects and Patients With Psoriasis Psoriasis | Phase 1 | 2022-07-29 |
| Unknown | A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Sol Patients With Advanced Solid Tumors | Phase 1 | 2022-05-31 |
| Unknown | A Study of ICP-033 in Patients With Advanced Solid Tumors Patients With Advanced Solid Tumors | Phase 1 | 2022-02-25 |
| Unknown | A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia Primary Immune Thrombocytopenia | Phase 2 | 2022-02-21 |
| Completed | A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclop Treatment-naїve Mantle Cell Lymphoma | Phase 3 | 2021-12-22 |
| Completed | DDI Study of Orelabrutinib Healthy Person | Phase 1 | 2021-12-16 |
| Unknown | A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations Advanced Solid Tumor | Phase 2 | 2021-12-15 |
| Active Not Recruiting | A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) Hematoma | Phase 1 / Phase 2 | 2021-11-16 |
| Recruiting | Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refrac DLBCL | Phase 2 | 2021-09-06 |
| Completed | A Phase I Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Study of ICP-332 in Healthy Su Healthy Subjects | Phase 1 | 2021-08-14 |
| Unknown | A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis Relapsing Remitting Multiple Sclerosis | Phase 2 | 2021-03-01 |
| Unknown | A Study of ICP-192 in Patients With Advanced Solid Tumors Advanced Solid Tumors, Urothelial Carcinoma, Cholangiocarcinoma | Phase 1 / Phase 2 | 2021-02-01 |
| Unknown | ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | 2021-01-08 |
| Recruiting | A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors Solid Tumors | Phase 1 / Phase 2 | 2020-09-27 |
| Unknown | A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory | Phase 1 / Phase 2 | 2020-07-28 |
| Completed | A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE) Systemic Lupus Erythematosus | Phase 1 / Phase 2 | 2020-07-09 |
| Unknown | An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer Bladder Urothelial Cancer | Phase 2 | 2020-05-27 |
| Completed | A Study of ICP-022 in Patients With R/R DLBCL Diffuse Large B Cell Lymphoma | Phase 2 | 2020-05-07 |
| Unknown | A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies Part 1：r/r B-cell Malignancies, Part 2：B-cell Malignancies | Phase 1 / Phase 2 | 2019-11-18 |
| Completed | A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory | Phase 2 | 2019-08-10 |
| Completed | ADME Study of [14C]ICP-022 in Healthy Males Healthy Volunteers | N/A | 2019-07-01 |
| Unknown | A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL PCNSL, Secondary Central Nervous System Lymphoma | Phase 2 | 2019-06-18 |
| Completed | A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL) MZL | Phase 2 | 2019-04-01 |
| Unknown | Clinical Study of ICP-192 in Solid Tumors Patients Solid Tumor | Phase 1 / Phase 2 | 2018-12-19 |
| Completed | Study of ICP-105 in Solid Tumors Patients Solid Tumor | Phase 1 | 2018-09-21 |
| Unknown | A Study to Evaluate ICP-022 in Patients With CLL/ SLL CLL/SLL | Phase 1 / Phase 2 | 2018-04-17 |
| Unknown | A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL) Mantle Cell Lymphoma | Phase 1 / Phase 2 | 2018-04-02 |